{"organizations": [], "uuid": "d66dbf995a51863a9f53eca1b93fb709a42585bf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/20/the-associated-press-halozyme-therapeutics-tops-street-4q-forecasts.html", "country": "US", "domain_rank": 767, "title": "Halozyme Therapeutics tops Street 4Q forecasts", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-20T23:49:00.000+02:00", "replies_count": 0, "uuid": "d66dbf995a51863a9f53eca1b93fb709a42585bf"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/20/the-associated-press-halozyme-therapeutics-tops-street-4q-forecasts.html", "ord_in_thread": 0, "title": "Halozyme Therapeutics tops Street 4Q forecasts", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "halozyme therapeutics inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}, {"name": "halozyme therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported fourth-quarter net income of $123.9 million, after reporting a loss in the same period a year earlier.\nThe San Diego-based company said it had profit of 85 cents per share.\nThe results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 66 cents per share.\nThe biopharmaceutical company posted revenue of $189.6 million in the period, also topping Street forecasts. Three analysts surveyed by Zacks expected $161.8 million.\nFor the year, the company reported net income of $63 million, or 45 cents per share, swinging to a profit in the period. Revenue was reported as $316.6 million.\nHalozyme Therapeutics expects full-year revenue in the range of $115 million to $125 million.\nHalozyme Therapeutics shares have declined almost 9 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $18.48, an increase of 47 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on HALO at https://www.zacks.com/ap/HALO", "external_links": [], "published": "2018-02-20T23:49:00.000+02:00", "crawled": "2018-02-21T00:05:13.013+02:00", "highlightTitle": ""}